{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:21:54Z","timestamp":1740108114984,"version":"3.37.3"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006389","name":"University of Geneva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Breast cancer (BC) is the most prevalent cancer in women and radiotherapy (RT) is an integral part of its treatment. High-level evidence guides clinical decisions, but given the abundance of guidelines, a\u00a0need to navigate within the evidence has been identified by the board of the Scientific Association of Swiss Radiation Oncology (SASRO). A\u00a0pilot project was initiated aiming to create an overview of recent clinically relevant evidence for BC RT, to make it easily available to (radiation) oncologists and radiation oncologists in training.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A\u00a0panel of 10\u00a0radiation oncology experts for BC RT, one expert in BC surgery, and one expert in BC medical oncology critically reviewed the relevant literature. The panel comprehensively represented different geographical regions of Switzerland as well as university, cantonal, and private institutions. We sought to create a\u00a0consensual overview of the most relevant questions in BC RT today, accompanied by the most recent and relevant available evidence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>From January 2023 to January 2024, the panel met four times to review and work on an initial draft. The final draft was reviewed and accepted by all panelists. We hereby publish this work to make it available to international audiences. After publication, the work will be made available to all SASRO members on the SASRO website. This work is to be updated every 2\u00a0years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The identified need was addressed with a\u00a0successful pilot project and will be further expanded upon in other tumor pathologies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00066-024-02332-5","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T22:19:16Z","timestamp":1733523556000},"page":"93-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating through recent evidence on locoregional breast cancer radiotherapy: an initiative by the scientific association of Swiss radiation oncology"],"prefix":"10.1007","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6490-9278","authenticated-orcid":false,"given":"Pelagia G.","family":"Tsoutsou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Lena","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnther","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Henke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Jeannerret-Sozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Linsenmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"L\u00f6ssl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Carla","family":"Valli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter P.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Zaugg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalil","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zwahlen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"1","key":"2332_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel\u00a0RL, Giaquinto\u00a0AN, Jemal\u00a0A (2024) Cancer statistics, 2024. CA A Cancer J Clinicians 74(1):12\u201349","journal-title":"CA A Cancer J Clinicians"},{"key":"2332_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-02075-w","author":"K Sanderson","year":"2023","unstructured":"Sanderson\u00a0K (2023) Huge leap in breast cancer survival rate. Nature. https:\/\/doi.org\/10.1038\/d41586-023-02075-w","journal-title":"Nature"},{"issue":"5","key":"2332_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1053\/j.seminoncol.2008.07.005","volume":"35","author":"DL Wickerham","year":"2008","unstructured":"Wickerham\u00a0DL et\u00a0al (2008) The half century of clinical trials of the national surgical adjuvant breast and bowel project. Semin Oncol 35(5):522\u2013529","journal-title":"Semin Oncol"},{"issue":"1","key":"2332_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck\u00a0N et\u00a0al (2019) Breast cancer. Nat Rev Dis Primers 5(1):66","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"2332_CR5","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa022152","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher\u00a0B et\u00a0al (2002) Twenty-year follow-up of a\u00a0randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N\u00a0Engl J Med 347(16):1233\u20131241","journal-title":"N Engl J Med"},{"issue":"9503","key":"2332_CR6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","volume":"366","author":"M Clarke","year":"2005","unstructured":"Clarke\u00a0M et\u00a0al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087\u20132106","journal-title":"Lancet"},{"issue":"9935","key":"2332_CR7","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","volume":"383","author":"P McGale","year":"2014","unstructured":"McGale\u00a0P et\u00a0al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127\u20132135","journal-title":"Lancet"},{"key":"2332_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ejca.2016.10.023","volume":"72","author":"F Cardoso","year":"2017","unstructured":"Cardoso\u00a0F et\u00a0al (2017) European breast cancer conference manifesto on breast centres\/units. Eur J Cancer 72:244\u2013250","journal-title":"Eur J Cancer"},{"issue":"8","key":"2332_CR9","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S1470-2045(23)00286-3","volume":"24","author":"D Pasquier","year":"2023","unstructured":"Pasquier\u00a0D et\u00a0al (2023) Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a\u00a0consensus recommendation from the EORTC imaging and breast cancer groups. Lancet Oncol 24(8):e331\u2013e343","journal-title":"Lancet Oncol"},{"issue":"1","key":"2332_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijrobp.2022.09.062","volume":"115","author":"M Goldberg","year":"2023","unstructured":"Goldberg\u00a0M et\u00a0al (2023) A\u00a0meta-analysis of trials of partial breast irradiation. Int J Radiat Oncol Biol Phys 115(1):60\u201372","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2332_CR11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S1470-2045(23)00018-9","volume":"24","author":"V Strnad","year":"2023","unstructured":"Strnad\u00a0V et\u00a0al (2023) Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a\u00a0GEC-ESTRO randomised, phase\u00a03, non-inferiority trial. Lancet Oncol 24(3):262\u2013272","journal-title":"Lancet Oncol"},{"issue":"2","key":"2332_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.prro.2023.11.001","volume":"14","author":"SF Shaitelman","year":"2024","unstructured":"Shaitelman\u00a0SF et\u00a0al (2024) Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: an ASTRO clinical practice guideline. Pract Radiat Oncol 14(2):112\u2013132","journal-title":"Pract Radiat Oncol"},{"key":"2332_CR13","doi-asserted-by":"publisher","first-page":"e389516","DOI":"10.1200\/EDBK_389516","volume":"43","author":"S Shickh","year":"2023","unstructured":"Shickh\u00a0S et\u00a0al (2023) Shared decision making in the care of patients with cancer. Am Soc Clin Oncol Educ Book 43:e389516","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2332_CR14","unstructured":"https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"issue":"11","key":"2332_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","volume":"34","author":"G Curigliano","year":"2023","unstructured":"Curigliano\u00a0G et\u00a0al (2023) Understanding breast cancer complexity to improve patient outcomes: the St Gallen international consensus conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol 34(11):970\u2013986","journal-title":"Ann Oncol"},{"issue":"2","key":"2332_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl\u00a0S et\u00a0al (2024) Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 35(2):159\u2013182","journal-title":"Ann Oncol"},{"issue":"27","key":"2332_CR17","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.21.00934","volume":"39","author":"M Brackstone","year":"2021","unstructured":"Brackstone\u00a0M et\u00a0al (2021) Management of the axilla in early-stage breast cancer: Ontario health (cancer care Ontario) and ASCO guideline. J\u00a0Clin Oncol 39(27):3056\u20133082","journal-title":"J Clin Oncol"},{"issue":"5","key":"2332_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.prro.2016.06.011","volume":"6","author":"M Morrow","year":"2016","unstructured":"Morrow\u00a0M et\u00a0al (2016) Society of surgical oncology-American society for radiation oncology-American society of clinical oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Pract Radiat Oncol 6(5):287\u2013295","journal-title":"Pract Radiat Oncol"},{"issue":"36","key":"2332_CR19","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1200\/JCO.2016.69.1188","volume":"34","author":"A Recht","year":"2016","unstructured":"Recht\u00a0A et\u00a0al (2016) Postmastectomy radiotherapy: an American society of clinical oncology, American society for radiation oncology, and society of surgical oncology focused guideline update. J\u00a0Clin Oncol 34(36):4431\u20134442","journal-title":"J Clin Oncol"},{"key":"2332_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.radonc.2020.04.059","volume":"149","author":"G Fastner","year":"2020","unstructured":"Fastner\u00a0G et\u00a0al (2020) ESTRO IORT task force\/ACROP recommendations for intraoperative radiation therapy with electrons (IOERT) in breast cancer. Radiother Oncol 149:150\u2013157","journal-title":"Radiother Oncol"},{"issue":"3","key":"2332_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.radonc.2018.04.009","volume":"128","author":"V Strnad","year":"2018","unstructured":"Strnad\u00a0V et\u00a0al (2018) ESTRO-ACROP guideline: interstitial multi-catheter breast brachytherapy as accelerated partial breast irradiation alone or as boost\u2014GEC-ESTRO breast cancer working group practical recommendations. Radiother Oncol 128(3):411\u2013420","journal-title":"Radiother Oncol"},{"issue":"1","key":"2332_CR22","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S1470-2045(21)00539-8","volume":"23","author":"I Meattini","year":"2022","unstructured":"Meattini\u00a0I et\u00a0al (2022) European society for radiotherapy and oncology advisory committee in radiation oncology practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol 23(1):e21\u2013e31","journal-title":"Lancet Oncol"},{"issue":"2","key":"2332_CR23","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S1470-2045(23)00534-X","volume":"25","author":"I Meattini","year":"2024","unstructured":"Meattini\u00a0I et\u00a0al (2024) International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European society for radiotherapy and oncology (ESTRO)-endorsed recommendations. Lancet Oncol 25(2):e73\u2013e83","journal-title":"Lancet Oncol"},{"issue":"10416","key":"2332_CR24","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(23)01082-6","volume":"402","author":"EBCTCG (Early Breast Cancer Trialists\u2019 Collaborative Group)","year":"2023","unstructured":"EBCTCG (Early Breast Cancer Trialists\u2019 Collaborative Group) (2023) Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16\u00a0trials. Lancet 402(10416):1991\u20132003","journal-title":"Lancet"},{"key":"2332_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102085","author":"O Kaidar-Person","year":"2023","unstructured":"Kaidar-Person\u00a0O et\u00a0al (2023) The Lucerne toolbox 2 to optimise axillary management for early breast cancer: a\u00a0multidisciplinary expert consensus. eClinicalMedicine. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102085","journal-title":"eClinicalMedicine"},{"issue":"10","key":"2332_CR26","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano\u00a0AE et\u00a0al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA 318(10):918\u2013926","journal-title":"JAMA"},{"issue":"12","key":"2332_CR27","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker\u00a0M et\u00a0al (2014) Radiotherapy or surgery of the axilla after a\u00a0positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a\u00a0randomised, multicentre, open-label, phase\u00a03 non-inferiority trial. Lancet Oncol 15(12):1303\u20131310","journal-title":"Lancet Oncol"},{"issue":"4","key":"2332_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1415340","volume":"373","author":"TJ Whelan","year":"2015","unstructured":"Whelan\u00a0TJ et\u00a0al (2015) Regional nodal irradiation in early-stage breast cancer. N\u00a0Engl J Med 373(4):307\u2013316","journal-title":"N Engl J Med"},{"issue":"4","key":"2332_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1415369","volume":"373","author":"PM Poortmans","year":"2015","unstructured":"Poortmans\u00a0PM et\u00a0al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N\u00a0Engl J Med 373(4):317\u2013327","journal-title":"N Engl J Med"},{"issue":"9935","key":"2332_CR30","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/S0140-6736(14)60192-6","volume":"383","author":"P Poortmans","year":"2014","unstructured":"Poortmans\u00a0P (2014) Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. Lancet 383(9935):2104\u20132106","journal-title":"Lancet"},{"issue":"9","key":"2332_CR31","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(22)00482-X","volume":"23","author":"SR de Wild","year":"2022","unstructured":"de Wild\u00a0SR et\u00a0al (2022) De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5\u2011year follow-up results of a\u00a0Dutch, prospective, registry study. Lancet Oncol 23(9):1201\u20131210","journal-title":"Lancet Oncol"},{"key":"2332_CR32","volume-title":"Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG oncology\/NSABP B-51\/RTOG 1304","author":"E Mamounas","year":"2023","unstructured":"Mamounas\u00a0E, Bandos\u00a0H, White\u00a0J et\u00a0al (2023) Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG oncology\/NSABP B\u201151\/RTOG 1304. 2023 San Antonio Breast Cancer Symposium. (Abstract GS02-07)"},{"issue":"11","key":"2332_CR33","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","volume":"9","author":"OD Gentilini","year":"2023","unstructured":"Gentilini\u00a0OD et\u00a0al (2023) Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol 9(11):1557\u20131564","journal-title":"JAMA Oncol"},{"key":"2332_CR34","unstructured":"https:\/\/ascopubs.org\/jco\/special-series\/2020\/local-regional-management-breast-cancer"},{"issue":"10350","key":"2332_CR35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(22)01246-6","volume":"400","author":"BH Chua","year":"2022","unstructured":"Chua\u00a0BH et\u00a0al (2022) Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3\u201107\/TROG 07.01): a\u00a0randomised, factorial, multicentre, open-label, phase\u00a03\u00a0study. Lancet 400(10350):431\u2013440","journal-title":"Lancet"},{"issue":"3","key":"2332_CR36","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ijrobp.2022.07.2320","volume":"114","author":"FA Vicini","year":"2022","unstructured":"Vicini\u00a0FA et\u00a0al (2022) NRG RTOG 1005: a\u00a0phase\u00a0III trial of hypo fractionated whole breast irradiation with concurrent boost vs. conventional whole breast irradiation plus sequential boost following lumpectomy for high risk early-stage breast cancer. Int J Radiat Oncol Biol Phys 114(3):S1","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"35","key":"2332_CR37","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1200\/JCO.20.00650","volume":"38","author":"I Meattini","year":"2020","unstructured":"Meattini\u00a0I et\u00a0al (2020) Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase\u00a0III APBI-IMRT-florence trial. J\u00a0Clin Oncol 38(35):4175\u20134183","journal-title":"J Clin Oncol"},{"issue":"28","key":"2332_CR38","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1200\/JCO.19.02750","volume":"38","author":"AM Brunt","year":"2020","unstructured":"Brunt\u00a0AM et\u00a0al (2020) Ten-year results of FAST: a\u00a0randomized controlled trial of 5\u2011fraction whole-breast radiotherapy for early breast cancer. J\u00a0Clin Oncol 38(28):3261\u20133272","journal-title":"J Clin Oncol"},{"issue":"10237","key":"2332_CR39","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","volume":"395","author":"A Murray Brunt","year":"2020","unstructured":"Murray Brunt\u00a0A et\u00a0al (2020) Hypofractionated breast radiotherapy for 1\u00a0week versus 3\u00a0weeks (FAST-Forward): 5\u2011year efficacy and late normal tissue effects results from a\u00a0multicentre, non-inferiority, randomised, phase\u00a03\u00a0trial. Lancet 395(10237):1613\u20131626","journal-title":"Lancet"},{"key":"2332_CR40","doi-asserted-by":"publisher","first-page":"109734","DOI":"10.1016\/j.radonc.2023.109734","volume":"185","author":"MC Aznar","year":"2023","unstructured":"Aznar\u00a0MC et\u00a0al (2023) ESTRO-ACROP guideline: recommendations on implementation of breath-hold techniques in radiotherapy. Radiother Oncol 185:109734","journal-title":"Radiother Oncol"},{"issue":"9","key":"2332_CR41","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/j.clon.2022.05.020","volume":"34","author":"T Kron","year":"2022","unstructured":"Kron\u00a0T et\u00a0al (2022) TROG 14.04: multicentre study of feasibility and impact on anxiety of DIBH in breast cancer patients. Clin Oncol 34(9):e410\u2013e419","journal-title":"Clin Oncol"},{"issue":"7","key":"2332_CR42","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jamaoncol.2022.1479","volume":"8","author":"D Vesprini","year":"2022","unstructured":"Vesprini\u00a0D et\u00a0al (2022) Effect of supine vs prone breast radiotherapy on acute toxic effects of the skin among women with large breast size: a\u00a0randomized clinical trial. JAMA Oncol 8(7):994\u20131000","journal-title":"JAMA Oncol"},{"key":"2332_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.radonc.2021.09.012","volume":"164","author":"O Kaidar-Person","year":"2021","unstructured":"Kaidar-Person\u00a0O et\u00a0al (2021) A\u00a0Delphi study and international consensus recommendations: the use of bolus in the setting of postmastectomy radiation therapy for early breast cancer. Radiother Oncol 164:115\u2013121","journal-title":"Radiother Oncol"},{"issue":"1","key":"2332_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.radonc.2014.11.030","volume":"114","author":"BV Offersen","year":"2015","unstructured":"Offersen\u00a0BV et\u00a0al (2015) ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol 114(1):3\u201310","journal-title":"Radiother Oncol"},{"issue":"4","key":"2332_CR45","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.ijrobp.2022.10.030","volume":"115","author":"H Jing","year":"2023","unstructured":"Jing\u00a0H et\u00a0al (2023) Individualized clinical target volume for irradiation of the supraclavicular region in breast cancer based on mapping of the involved ipsilateral supraclavicular lymph nodes. Int J Radiat Oncol Biol Phys 115(4):922\u2013932","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2332_CR46","unstructured":"https:\/\/www.rtog.org\/LinkClick.aspx?fileticket=eVB451KQ83M%3d&tabid=429"},{"key":"2332_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.radonc.2019.04.010","volume":"137","author":"O Kaidar-Person","year":"2019","unstructured":"Kaidar-Person\u00a0O et\u00a0al (2019) ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. Radiother Oncol 137:159\u2013166","journal-title":"Radiother Oncol"},{"issue":"6","key":"2332_CR48","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1470-2045(06)70699-4","volume":"7","author":"JR Owen","year":"2006","unstructured":"Owen\u00a0JR et\u00a0al (2006) Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a\u00a0randomised trial. Lancet Oncol 7(6):467\u2013471","journal-title":"Lancet Oncol"},{"issue":"4","key":"2332_CR49","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","volume":"9","author":"SM Bentzen","year":"2008","unstructured":"Bentzen\u00a0SM et\u00a0al (2008) The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a\u00a0randomised trial. Lancet Oncol 9(4):331\u2013341","journal-title":"Lancet Oncol"},{"issue":"9618","key":"2332_CR50","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","volume":"371","author":"SM Bentzen","year":"2008","unstructured":"Bentzen\u00a0SM et\u00a0al (2008) The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a\u00a0randomised trial. Lancet 371(9618):1098\u20131107","journal-title":"Lancet"},{"issue":"6","key":"2332_CR51","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0906260","volume":"362","author":"TJ Whelan","year":"2010","unstructured":"Whelan\u00a0TJ et\u00a0al (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N\u00a0Engl J Med 362(6):513\u2013520","journal-title":"N Engl J Med"},{"issue":"10099","key":"2332_CR52","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0140-6736(17)31145-5","volume":"390","author":"CE Coles","year":"2017","unstructured":"Coles\u00a0CE et\u00a0al (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5\u2011year results from a\u00a0multicentre, randomised, controlled, phase\u00a03, non-inferiority trial. Lancet 390(10099):1048\u20131060","journal-title":"Lancet"},{"issue":"3","key":"2332_CR53","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","volume":"20","author":"SL Wang","year":"2019","unstructured":"Wang\u00a0SL et\u00a0al (2019) Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a\u00a0randomised, non-inferiority, open-label, phase\u00a03\u00a0trial. Lancet Oncol 20(3):352\u2013360","journal-title":"Lancet Oncol"},{"key":"2332_CR54","doi-asserted-by":"publisher","unstructured":"Wang S\u2011L et\u00a0al Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a\u00a0multicenter, randomized controlled trial from China. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/jco.20.01024","DOI":"10.1200\/jco.20.01024"},{"key":"2332_CR55","doi-asserted-by":"publisher","unstructured":"Offersen BV et\u00a0al Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a\u00a0randomized phase\u00a0III trial: the DBCG HYPO trial. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/jco.20.01363","DOI":"10.1200\/jco.20.01363"},{"issue":"10237","key":"2332_CR56","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","volume":"395","author":"A Murray Brunt","year":"2020","unstructured":"Murray Brunt\u00a0A et\u00a0al (2020) Hypofractionated breast radiotherapy for 1\u00a0week versus 3\u00a0weeks (FAST-Forward): 5\u2011year efficacy and late normal tissue effects results from a\u00a0multicentre, non-inferiority, randomised, phase\u00a03\u00a0trial. Lancet 395(10237):1613\u20131626","journal-title":"Lancet"},{"issue":"10394","key":"2332_CR57","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1016\/S0140-6736(23)00619-0","volume":"401","author":"CE Coles","year":"2023","unstructured":"Coles\u00a0CE et\u00a0al (2023) Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a\u00a0multicentre, phase\u00a03, non-inferiority, open-label, randomised controlled trial. Lancet 401(10394):2124\u20132137","journal-title":"Lancet"},{"issue":"3","key":"2332_CR58","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S1470-2045(14)71221-5","volume":"16","author":"IH Kunkler","year":"2015","unstructured":"Kunkler\u00a0IH et\u00a0al (2015) Breast-conserving surgery with or without irradiation in women aged 65\u00a0years or older with early breast cancer (PRIME II): a\u00a0randomised controlled trial. Lancet Oncol 16(3):266\u2013273","journal-title":"Lancet Oncol"},{"issue":"7","key":"2332_CR59","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJMoa2302344","volume":"389","author":"TJ Whelan","year":"2023","unstructured":"Whelan\u00a0TJ et\u00a0al (2023) Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer. N\u00a0Engl J Med 389(7):612\u2013619","journal-title":"N Engl J Med"},{"issue":"4","key":"2332_CR60","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/JCO.23.02270","volume":"42","author":"R Jagsi","year":"2024","unstructured":"Jagsi\u00a0R et\u00a0al (2024) Omission of radiotherapy after breast-conserving surgery for women with breast cancer with low clinical and genomic risk: 5\u2011year outcomes of IDEA. J\u00a0Clin Oncol 42(4):390\u2013398","journal-title":"J Clin Oncol"},{"issue":"7","key":"2332_CR61","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMe2216133","volume":"388","author":"AY Ho","year":"2023","unstructured":"Ho\u00a0AY, Bellon\u00a0JR (2023) Overcoming resistance\u2014omission of radiotherapy for low-risk breast cancer. N\u00a0Engl J Med 388(7):652\u2013653","journal-title":"N Engl J Med"},{"issue":"18","key":"2332_CR62","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1056\/NEJMc2310656","volume":"389","author":"A Recht","year":"2023","unstructured":"Recht\u00a0A (2023) Omitting radiotherapy in luminal A breast cancer. N\u00a0Engl J Med 389(18):1727","journal-title":"N Engl J Med"},{"issue":"2","key":"2332_CR63","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2019.06.014","volume":"105","author":"MC Ward","year":"2019","unstructured":"Ward\u00a0MC et\u00a0al (2019) Radiation therapy without hormone therapy for women age 70 or above with low-risk early breast cancer: a\u00a0microsimulation. Int J Radiat Oncol Biol Phys 105(2):296\u2013306","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2332_CR64","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04134598?cond=breast&term=europa&rank=1"},{"issue":"3","key":"2332_CR65","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ijrobp.2021.01.047","volume":"110","author":"JM Purswani","year":"2021","unstructured":"Purswani\u00a0JM et\u00a0al (2021) Breast conservation in women with autoimmune disease: the role of active autoimmune disease and hypofractionation on acute and late toxicity in a\u00a0case-controlled series. Int J Radiat Oncol Biol Phys 110(3):783\u2013791","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2332_CR66","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1016\/j.prro.2021.10.008","volume":"12","author":"JM Purswani","year":"2022","unstructured":"Purswani\u00a0JM et\u00a0al (2022) Toxicity and cosmetic outcome of breast irradiation in women with breast cancer and autoimmune connective tissue disease: the role of fraction and field size. Pract Radiat Oncol 12(2):e90\u2013e100","journal-title":"Pract Radiat Oncol"},{"issue":"12","key":"2332_CR67","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.1016\/S1470-2045(21)00425-3","volume":"22","author":"J Thariat","year":"2021","unstructured":"Thariat\u00a0J et\u00a0al (2021) Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes. Lancet Oncol 22(12):e562\u2013e574","journal-title":"Lancet Oncol"},{"issue":"3","key":"2332_CR68","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.clon.2005.11.013","volume":"18","author":"C Turnbull","year":"2006","unstructured":"Turnbull\u00a0C, Mirugaesu\u00a0N, Eeles\u00a0R (2006) Radiotherapy and genetic predisposition to breast cancer. Clin Oncol 18(3):257\u2013267","journal-title":"Clin Oncol"},{"issue":"2","key":"2332_CR69","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ijrobp.2021.09.026","volume":"112","author":"BV Chapman","year":"2022","unstructured":"Chapman\u00a0BV et\u00a0al (2022) Breast radiation therapy-related treatment outcomes in patients with or without germline mutations on multigene panel testing. Int J Radiat Oncol Biol Phys 112(2):437\u2013444","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"2332_CR70","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.ejca.2005.02.037","volume":"41","author":"YM Kirova","year":"2005","unstructured":"Kirova\u00a0YM et\u00a0al (2005) Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA\u00a01 and BRCA\u00a02 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 41(15):2304\u20132311","journal-title":"Eur J Cancer"},{"issue":"4","key":"2332_CR71","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1053\/srao.2002.35254","volume":"12","author":"L Pierce","year":"2002","unstructured":"Pierce\u00a0L (2002) Radiotherapy for breast cancer in BRCA\u00a01\/BRCA\u00a02 carriers: clinical issues and management dilemmas. Semin Radiat Oncol 12(4):352\u2013361","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"2332_CR72","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10549-009-0685-6","volume":"120","author":"YM Kirova","year":"2010","unstructured":"Kirova\u00a0YM et\u00a0al (2010) Is the breast-conserving treatment with radiotherapy appropriate in BRCA\u00a01\/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat 120(1):119\u2013126","journal-title":"Breast Cancer Res Treat"},{"key":"2332_CR73","doi-asserted-by":"publisher","first-page":"102417","DOI":"10.1016\/j.ctrv.2022.102417","volume":"108","author":"I Meattini","year":"2022","unstructured":"Meattini\u00a0I et\u00a0al (2022) Integrating radiation therapy with targeted treatments for breast cancer: from bench to bedside. Cancer Treat Rev 108:102417","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"2332_CR74","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","volume":"27","author":"MY Halyard","year":"2009","unstructured":"Halyard\u00a0MY et\u00a0al (2009) Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase\u00a0III trial N9831. J\u00a0Clin Oncol 27(16):2638\u20132644","journal-title":"J Clin Oncol"},{"key":"2332_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082278","author":"K Debbi","year":"2023","unstructured":"Debbi\u00a0K et\u00a0al (2023) Interaction between radiation therapy and targeted therapies in HER2-positive breast cancer: literature review, levels of evidence for safety and recommendations for optimal treatment sequence. Cancers. https:\/\/doi.org\/10.3390\/cancers15082278","journal-title":"Cancers"},{"key":"2332_CR76","doi-asserted-by":"publisher","first-page":"109805","DOI":"10.1016\/j.radonc.2023.109805","volume":"186","author":"V Salvestrini","year":"2023","unstructured":"Salvestrini\u00a0V et\u00a0al (2023) Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a\u00a0systematic review and meta-analysis. Radiother Oncol 186:109805","journal-title":"Radiother Oncol"},{"issue":"5","key":"2332_CR77","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ijrobp.2024.01.001","volume":"118","author":"S Verma","year":"2024","unstructured":"Verma\u00a0S et\u00a0al (2024) Immunotherapy and radiation therapy sequencing in breast cancer: a\u00a0systematic review. Int J Radiat Oncol Biol Phys 118(5):1422\u20131434","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"2332_CR78","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.radonc.2022.10.023","volume":"177","author":"L Visani","year":"2022","unstructured":"Visani\u00a0L et\u00a0al (2022) Safety of CDK4\/6\u00a0inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer. Radiother Oncol 177:40\u201345","journal-title":"Radiother Oncol"},{"issue":"12","key":"2332_CR79","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","volume":"8","author":"P Loap","year":"2022","unstructured":"Loap\u00a0P et\u00a0al (2022) Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: the phase\u00a01 olaparib and radiation therapy for triple-negative breast cancer trial. JAMA Oncol 8(12):1802\u20131808","journal-title":"JAMA Oncol"},{"issue":"25","key":"2332_CR80","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt\u00a0ANJ et\u00a0al (2021) Adjuvant olaparib for patients with \u3008i\u3009BRCA\u00a01\u3008\/i\u3009- or \u3008i\u3009BRCA\u00a02\u3008\/i\u3009-mutated breast cancer. N\u00a0Engl J Med 384(25):2394\u20132405","journal-title":"N Engl J Med"},{"issue":"4","key":"2332_CR81","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ijrobp.2017.04.030","volume":"99","author":"WA Woodward","year":"2017","unstructured":"Woodward\u00a0WA et\u00a0al (2017) A\u00a0phase\u00a02\u00a0study of capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys 99(4):777\u2013783","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"2332_CR82","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda\u00a0N et\u00a0al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N\u00a0Engl J Med 376(22):2147\u20132159","journal-title":"N Engl J Med"},{"issue":"3","key":"2332_CR83","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","volume":"24","author":"SGC Kroeze","year":"2023","unstructured":"Kroeze\u00a0SGC et\u00a0al (2023) Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol 24(3):e121\u2013e132","journal-title":"Lancet Oncol"},{"issue":"1","key":"2332_CR84","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3390\/curroncol30010088","volume":"30","author":"CH Abeloos","year":"2023","unstructured":"Abeloos\u00a0CH et\u00a0al (2023) Different re-irradiation techniques after breast-conserving surgery for recurrent or new primary breast cancer. Curr Oncol 30(1):1151\u20131163","journal-title":"Curr Oncol"},{"key":"2332_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.100640","author":"S Fattahi","year":"2021","unstructured":"Fattahi\u00a0S et\u00a0al (2021) Reirradiation for locoregional recurrent breast cancer. Adv Radiat Oncol. https:\/\/doi.org\/10.1016\/j.adro.2020.100640","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"2332_CR86","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ijrobp.2020.12.029","volume":"110","author":"JM Hannoun-Levi","year":"2021","unstructured":"Hannoun-Levi\u00a0JM et\u00a0al (2021) Salvage mastectomy versus second conservative treatment for second Ipsilateral breast tumor event: a\u00a0propensity score-matched cohort analysis of the GEC-ESTRO breast cancer working group database. Int J Radiat Oncol Biol Phys 110(2):452\u2013461","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2332_CR87","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jamaoncol.2019.4320","volume":"6","author":"DW Arthur","year":"2020","unstructured":"Arthur\u00a0DW et\u00a0al (2020) Effectiveness of breast-conserving surgery and 3\u2011dimensional conformal partial breast reirradiation for recurrence of breast cancer in the Ipsilateral breast: the NRG oncology\/RTOG 1014 phase\u00a02 clinical trial. JAMA Oncol 6(1):75\u201382","journal-title":"JAMA Oncol"},{"issue":"2","key":"2332_CR88","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-021-06206-7","volume":"188","author":"I Chen","year":"2021","unstructured":"Chen\u00a0I et\u00a0al (2021) Salvage of locally recurrent breast cancer with repeat breast conservation using 45\u202fGy hyperfractionated partial breast re-irradiation. Breast Cancer Res Treat 188(2):409\u2013414","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2332_CR89","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.radonc.2013.03.026","volume":"108","author":"JM Hannoun-Levi","year":"2013","unstructured":"Hannoun-Levi\u00a0JM et\u00a0al (2013) Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO breast cancer working group. Radiother Oncol 108(2):226\u2013231","journal-title":"Radiother Oncol"},{"key":"2332_CR90","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.breast.2020.01.003","volume":"49","author":"L Montagne","year":"2020","unstructured":"Montagne\u00a0L, Hannoun\u00a0A, Hannoun-Levi\u00a0J\u2011M (2020) Second conservative treatment for second ipsilateral breast tumor event: a\u00a0systematic review of the different re-irradiation techniques. Breast 49:274\u2013280","journal-title":"Breast"},{"issue":"2","key":"2332_CR91","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.clon.2017.11.004","volume":"30","author":"O Kaidar-Person","year":"2018","unstructured":"Kaidar-Person\u00a0O, Oldenborg\u00a0S, Poortmans\u00a0P (2018) Re-irradiation and hyperthermia in breast cancer. Clin Oncol 30(2):73\u201384","journal-title":"Clin Oncol"},{"key":"2332_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030606","author":"M Notter","year":"2020","unstructured":"Notter\u00a0M et\u00a0al (2020) Combined wIRA-hyperthermia and hypofractionated re-irradiation in the treatment of locally recurrent breast cancer: evaluation of therapeutic outcome based on a\u00a0novel size classification. Cancers. https:\/\/doi.org\/10.3390\/cancers12030606","journal-title":"Cancers"},{"issue":"10","key":"2332_CR93","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","volume":"23","author":"N Andratschke","year":"2022","unstructured":"Andratschke\u00a0N et\u00a0al (2022) European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol 23(10):e469\u2013e478","journal-title":"Lancet Oncol"},{"issue":"18","key":"2332_CR94","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1200\/JCO.23.00293","volume":"41","author":"BL Andersen","year":"2023","unstructured":"Andersen\u00a0BL et\u00a0al (2023) Management of anxiety and depression in adult survivors of cancer: ASCO guideline update. J\u00a0Clin Oncol 41(18):3426\u20133453","journal-title":"J Clin Oncol"},{"issue":"28","key":"2332_CR95","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.23.00857","volume":"41","author":"LE Carlson","year":"2023","unstructured":"Carlson\u00a0LE et\u00a0al (2023) Integrative oncology care of symptoms of anxiety and depression in adults with cancer: society for integrative oncology\u2014ASCO guideline. J\u00a0Clin Oncol 41(28):4562\u20134591","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"2332_CR96","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1200\/JCO.2013.53.4495","volume":"32","author":"JE Bower","year":"2014","unstructured":"Bower\u00a0JE et\u00a0al (2014) Screening, assessment, and management of fatigue in adult survivors of cancer: an American society of clinical oncology clinical practice guideline adaptation. J\u00a0Clin Oncol 32(17):1840\u20131850","journal-title":"J Clin Oncol"},{"issue":"13","key":"2332_CR97","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1200\/JCO.22.02171","volume":"41","author":"GE Naoum","year":"2023","unstructured":"Naoum GE, Taghian AG (2023) Endocrine Treatment for 5 Years or Radiation for 5 Days for Patients With Early Breast Cancer Older Than 65 Years: Can We Do It Right? J Clin Oncol 41(13):2331\u20132336. https:\/\/doi.org\/10.1200\/JCO.22.02171","journal-title":"J Clin Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02332-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-024-02332-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-024-02332-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T14:03:36Z","timestamp":1737554616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-024-02332-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2332"],"URL":"https:\/\/doi.org\/10.1007\/s00066-024-02332-5","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.G.\u00a0Tsoutsou, A.-L.\u00a0Eberhardt, G.\u00a0Gruber, G.\u00a0Henke, W.\u00a0Jeannerret-Sozzi, C.\u00a0Linsenmeier, K.\u00a0L\u00f6ssl, M.-C.\u00a0Valli, W.P.\u00a0Weber, K.\u00a0Zaugg, K.\u00a0Zaman, and D.\u00a0Zwahlen declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}